Guest Editor letter
Board of Directors
1*Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC)
2*Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial
3*Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC)
4*The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum based chemotherapy. A collaboration of MITO, Mango, AGO Study Group, BGOG, ENGOT, and GCIG
A01*Italian cohort of nivolumab Expanded Access Programme (EAP)
A02*Low dose computed tomography scan (LDCT) screening versus empiric surveillance in asbestos exposed subjects
A03*Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
A04Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC)
A05SQUIRE
A06Patient-centred approach in a multicenter national study (E-Lung)
A07Crizotinib in ROS1 rearranged or MET deregulated Non-Small-Cell Lung Cancer (NSCLC)
A08SMO mutations role in malignant pleural mesothelioma
A09Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer
A10Oral metronomic Vinorelbine (OMV) in elderly pts with advanced NSCLC
A11Molecular profiling in advanced non-small-cell lung cancer
A12Cisplatin-raltitrexed vs cisplatin-pemetrexed in the treatment of advanced pleural mesothelioma. final results of a network meta-analysis
A13Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC)
A14Economic burden of patients with Malignant Pleural Mesothelioma in a high prevalence center
A15Evaluation of MET gene status in malignant mesothelioma by fluorescent in situ hybridization
A16A review of pharmacological costs of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations
A17Correlation of metabolic information on 18F-FDG PET with the tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) candidate to upfront surgery
A18Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis
A19The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines
A20Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience
A21Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment
A22Nivolumab in patients with previously treated advanced NSCLC in clinical practice and correlation with immunological characteristics
A23Emerging role of liquid biopsy in detection of EGFR mutations from metastatic Lung Adenocarcinomas (mLA)
A24Nivolumab in non small cell lung cancer
A25The role of health professionals in informing patients with pulmonary diseases to stop smoking
A26Detection of EGFR mutations in tissue and plasma of NSCLC Patients
A27Weekly Epirubicin as palliative treatment in patients with malignant pleural mesothelioma (MPM)
A28TILs evaluation in early stages of NSCLC
A29Predictive role of absolute lymphocyte count (alc) and neutrophil/lymphocyte ratio (nlr) in patients with metastatic non small cell lung cancer (nsclc) treated with nivolumab
A30Results of safety run-in part in Metal (METformin in Advanced Lung cancer) trial
A31CT-guided fine-needle aspiration biopsy of pulmonary lesions under 15 mm of diameter
A32Observational prospective study to evaluate survival, quality of life and cost of oncologic treatments for advanced non small cell lung cancer (NSCLC) patients that progressed after a first line of treatment
A33The predictive role of peripheral blood lymphocytes (PBLs) immunophenotype in patients with advanced non-small-cell lung cancer (NSCLC) and renal-cell carcinoma (mRCC) undergoing nivolumab
A34Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging
A35A possible correlation with the response in patients with metastatic lung caner
A36Prolactin as a possible predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)
A37Lung cancer patients and unplanned presentations to hospital
A38Peritoneal carcinomatosis in non-small celllung cancer
A39Toxicity profile of afatinib in advanced EGFR mutated NSCLC treatment
A40Treatment in advanced malignant pleural mesothelioma after chemotherapy standard
A41Our experience with an alternative schedule of metronomic Vinorelbine (mVNR) in NSCLC
A42A data collection representative of an outcome analysis in advanced Non Small Cell Lung Cancer (NSCLC) expressing EGFR mutations after failure of first line therapy with Tyrosine Kinase Inhibitors (TKIs) with careful on post progression survival
A43Gemcitabine as single agent second line treatment in patients with advanced wild-type EGFR, negative ALK non-small cell lung cancer
A44Maintenance treatment with pemetrexed in NSCLC
B01*A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma
B02*Ramucirumab as second line therapy in metastatic gastric cancer (MGC)
B03Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer
B04Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
B05Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)
B06Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
B07An Italian Cost-Effectiveness Analysis of Paclitaxel Albumin (nab®-paclitaxel) + Gemcitabine vs Gemcibatine alone for Metastatic Pancreatic Cancer Patients
B08Characteristics and outcomes of advanced gastric cancer patients treated with at least three lines of chemotherapy
B09A prognostic model using inflammatory response markers in metastatic gastric cancer (GC) pts before first-line chemotherapy
B10Mixed meta-analysis of treatment options for locally advanced oesophageal squamous-cell carcinoma
B11Prognostic significance of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma
B12Enhancer of zeste homolog 2 (EZH2) expression in G1 -G2 Pancreatic Neuroendocrine Tumor (pNET)
B13Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs)
B14The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab resistant gastric cancer cell lines
B15Polymorphism of CDH1 Promoter Is a Predictor of Clinical Outcome in Patients with Metastatic Gastric Cancer Treated with chemotherapy
B16HER2/HER3 pathway in biliary tract cancers
B17Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs)
B18GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab
B19Impact of VEGF and VEGFR single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine tumors
B20Second-line chemotherapy in advanced pancreatic cancer patients before nab-paclitaxel introduction. Retrospective study in Reggio Emilia Clinical Cancer Centre
B21Mismatch repair protein expression and inflammation in human pancreatic cancer
B22Appendiceal neuroendocrine tumors
B23Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2 amplified gastric cancer (GC) cell lines
B24Hepatic arterial infusion of Polythylene Glycol drug-eluting beads for Primary liver cancer therapy
B25Gastrointestinal stromal tumors associated with other malignancies. Chance phenomenon or causal relationship? A series of 75 patients
B26CROSS regimen for Oesophageal Cancer
B27Pathogenic and prognostic role of VEGF and VEGFR single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine neoplasms
B28Safety of Lanreotide 120 mg ATG in combination with metformin in patients with progressive advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study
B29An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort
B30Adjuvant chemotherapy in stage II and III resected gastric cancer
B31Clinical management of metastatic gastric cancer
B32HER-2 in gastric cancer
B33Perioperative chemotherapy in gastric cancer
B34Weekly cisplatin, leucovorin and 5Fluorouracile (PFL) as first line chemotherapy in selected patients with advanced gastric cancer
B35Neo-adjuvant treatment in patients with pancreatic cancer with nab-paclitaxel and gemcitabine
B36FOLFIRINOX for locally advanced and metastatic pancreatic cancer
B37Trastuzumab plus chemotherapy in the treatment of HER-2 –positive, advanced, gastric or gastro-esophageal junction cancer
B38Adjuvant treatment in gastric cancer patients with radiochemotherapy
C01*The detection of AR-V7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
C02*Modified BEP chemotherapy in patients with testicular germ-cell tumors treated at a Comprehensive Cancer Center
C03Brain and pancreatic metastases
C04Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel
C05Nivolumab in metastatic renal cell carcinoma (mRCC) patients
C06Radium-223 (Ra-223) Re-treatment (Re-tx)
C07Prognostic role of inflammatory markers in Mestatatic Renal Cell Carcinoma (mRCC)
C08Treament options in advanced castration-resistant, docetaxel-resistant prostate cancer (acrdrpc). final results of a network meta-analysis
C09Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
C10First-line PAzopanib in NOn-clear cell Renal cArcinoMA
C11Multicenter retrospective study on new biomarkers predictive of response to sunitinib in metastatic renal cell carcinoma
C12START (Active Surveillance or Radical Treatment for newly diagnosed patients with a localized, low risk, prostate cancer)
C13A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results
C14Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU)
C15Over the years change in prostate cancer management through the multidisciplinary team at a community hospital
C16Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents
C17Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy
C18Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC)
C19Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP)
C20Prostate cancer patients with cardiovascular risk factors
C21First Italian Multicentre Experience in using Ra-223 in patients with metastatic castration resistant prostate cancer (mCRPC)
C22Effectiveness of Axitinib second-line therapy for metastatic renal cell carcinoma
C23Vinflunine for patients with urothelial carcinoma resistant to first-line platinum-containing chemotherapy. A pooled analysis of efficacy and safety results in the real-world setting
C24Prognostic assessment in Abiraterone Acetate (AA) post-Docetxel (DOC) mCRPC cohort
C25Vinflunine (VFL) maintenance therapy in metastatic urothelial carcinoma (UC) after response to 1st line platinum-based chemotherapy (CT)
C26Treament options in advanced castration-resistant, prostate cancer (acrpc). preliminary results of a network meta-analysis
C27A retrospective multicenter characterization of patients with metastatic renal cell carcinoma
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel
C29Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer
D02*Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial
D03*Liver resection for colorectal liver metastases
D04Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer
D05FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD)
D06Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC)
D07Phase II open-label single-arm study of pre-operative panitumumab and external pelvic radiotherapy (RTE) in locally advanced rectal cancer (LARC) patients (pts) (RaP/STAR-03 Study)
D08The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis
D09Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)
D10May mutational status influence the metastatic pattern of colorectal cancer patients?
D11A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer (mCRC)
D12TRUST
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
D14Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients
D15Patients with borderline resectable colorectal cancer liver metastases (CLM)
D16BRAF mutation and Microsatellite status in stage II and III colorectal cancers
D17Regorafenib in previously treated metastatic colorectal cancer (mCRC)
D18“TRAP1 7-protein signature” predicts clinical outcome in human metastatic colorectal carcinoma
D19Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies
D20Serum metabolomic as biomarkers to differentiate early from metastatic disease in elderly colorectal cancer (crc) patients
D21Tumor-infiltrating lymphocytes (tils) density as prognostic determinant in stage ii colorectal cancer
D22PACER – A multicentre, single-arm, two-stage, phase 2 study of panitumumab in patients with cetuximab-refractory metastatic colorectal cancer (mCRC)
D23Pharmacogenomic evaluation of single nucleotide polymorphisms associated with oxaliplatin-induced peripheral neuropathy
D24Is the benefit of adjuvant chemotherapy limited to high-risk stage ii colorectal cancer?
D25Treatment of patients with metastatic colorectal cancer in a real-word scenario
D26Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer
D27Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)
D28The FUNNEL
D29Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy
D30Angiogenesis evaluation in locally advanced colo-rectal and gastric cancers by probe-based Confocal Laser Endomicroscopy (pCLE)
D31Outcomes of elderly chemorefractory metastatic colorectal (mCRC) patients (pts) treated with regorafenib
D32Left versus right side primary tumor
D33Transarterial Chemoembolization using Polythylene Glycol drug-eluting beads pre-charged with irinotecan (LIFIRI®) for the treatment of Metastatic liver cancer
D34Italian adaptation of the “Fantastic Lifestyle Checklist” for the evaluation of the change of lifestyles in patients with carcinoma of the colon and rectum in follow-up
D35A systematic review of the safety profile of bolus, continuous infusion of 5-fu and capecitabine in combination with oxaliplatin in the treatment of colorectal cancer patients
D36A prospective, observational trial to further assess safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mcrc) in routine clinical practice (correlate)
D37Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib
D38Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using 18fluorine-2-deoxy-d-glucose positron emission tomography-computed tomography
D39Observational study for MTHFR, TSER and DPYD gene mutation-associated toxicity and response in patients with rectal cancer receiving pre-operative chemo-radiotherapy
D40Transdermal Granisetron for the prevention of chemotherapy-induced nausea and vomiting in metastatic colorectal cancer patients with high risk of bowel obstruction treated with Temozolomide
D41Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer
D42Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluiting Beads (DEBIRI) in Refractory Liver Colorectal Cancer Metastases
D43Capecitabine and Regorafenib-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer
D44The overall survival of patients affected by metastatic colorectal cancer before and after “monoclonal antibodies era”
D45Prevention of regorafenib related skin toxicity in refractory metastatic colorectal cancer (mCRC) patients (pts)
D46Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
D47REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)
D48Monoinstitutional retrospective analysis of metronomic capecitabine (mc) schedule in the treatment of metastatic colorectal cancer
D49Phase ii study of mytomicin-c plus uft/lv in patients with metastatic colorectal cancer refractory to standard chemotherapy. subgroup analysis of predictive variables in discriminating early progressors
D50Monocentric survey about the use of Raltitrexed in the daily clinical practice for patients with metastatic colorectal cancer
E01*Effects of simultaneous care on quality of life of advanced cancer patients. A multicenter controlled randomised clinical trial
E02Awareness and consideration of malnutrition among italian oncologists
E03Prevalence study on potential drug-drug interaction in piacenza hospital onco-haematology department
E04Frequency and intensity of symptoms and disease awareness in a large mono-institutional series of Malignant Pleural Mesothelioma (MPM) patients followed within a simultaneous care program
E05Oncology Network ASL1 Abruzzo
E06Activation of Palliative Cares by hospital oncologists
E07Pre-graduate internship in the medical oncology department
E08A pilot study of simultaneous care in oncologic patients
E09Promoting healthy lifestyles. Additional results of an experimental study about the benefit of mind-body practice for cancer survivors
E10Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin
E11The association between infections and the outcome of chemotherapy programs for colorectal cancer patients
E12Psychological and physical benefits in metastatic cancer patients using Tibetan Singing Bowls. A pilot study in an Italian Oncology Unit
F01*Dose-dense adjuvant chemotherapy, treatment-induced amenorrhea and overall survival in premenopausal breast cancer patients
F02*Ki67, tumor stage (TS) and axillary node metastases (ANMs)
F03*The impact of reproductive factors and oral contraception on breast cancer risk in women with brca mutation or family history of breast cancer
F04An international multicentre hospital-based retrospective cohort study evaluating the prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients
F05Choices of first-line therapy in her2-ve advanced breast cancer (abc) patients (pts). prelimary results of the gim-13 - ambra study
F06Integrin a5 is an independent prognosis factor and a potential therapeutic target for breast cancer bone metastasis
F07Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients
F08Dose-dence adjuvant chemotherapy in early breast cancer
F09Prognostic Impact of Interval Breast Cancer Detection in Women with pT1aN0M0 Breast Cancer with HER2-positive Status
F10Breast cancer with synchronous and metachronous metastatic spreading. A single institution experience
F11Prognostic impact of Ki67 for resected early stage pure Invasive Lobular breast Cancer (ILC)
F12Concurrent versus sequential adjuvant chemo-endocrine therapy in early stage hormone receptor-positive breast cancer patients
F13Beyond clinical trials
F14Last-line treatment of luminal metastatic breast cancer
F15Treatment strategies in patients with Metastatic Breast Cancer
F16Preventing chemotherapy-induced alopecia by scalp cooling
F17The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy
F18Relationship between HER-2 amplification and tumor infiltrating lymphocytes in breast cancer patients treated with neoadjuvant trastuzumab
F19BRCA mutations and IGF-R1 expression in modulating sensitivity to Trastuzumab in patients with HER2-positive breast cancer
F20Metronomic vinorelbine, cyclophosphamide plus capecitabine (VEX) combination
F21Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC)
F22Maintenance hormonal therapy (MHT) in metastatic breast cancer (MBC) patients treated with first-line chemotherapy
F23Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial
F24Triple-negative breast cancer and BRCA mutation
F25Impact of hormonal receptor status on prognosis in HER2 positive breast cancer
F26A case series of sporadic breast and ovarian cancers in Salentinian families with BRCA mutation-associated Hereditary Breast and Ovarian Cancer (HBOC) syndrome
F27Tumor infiltrating lymphocytes in triple negative breast cancer and correlations with prognosis
F28Microvascular density and mast cell density positive to tryptase correlate with c-Kit receptor expression in early breast cancer patients
F295-fluorouracil degradation rate (5-FU-DR) could predict toxicity in breast cancer patients treated with capecitabine
F30Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma
F31Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus
F32Efficacy and safety of everolimus (eve) and exemestane (exe) in postmenopausal hormone-receptor positive (hr+) advanced breast cancer (abc) patients (pts) beyond clinical trials
F33Potential role of PLR and NLR in clinical decision making in locally advanced breast cancer
F34Retrospective observational analysis of bevacizumab (BV) plus paclitaxel (TXL) as first line treatment in metastatic HER2 negative breast cancer (BC)
F35Young women with metastatic breast cancer (mbc)
F36It's not the quality but the quantity
F37Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer
F38Assessment of obsessive thoughts and worries in women with breast cancer
F39Safety of Eribulin plus Trastuzumab in pre-treated HER2-positive advanced breast cancer (ABC) patients
F40TP53 germline mutation testing in early onset breast cancer
F41Prognostic role of pregnancy in breast cancer patients. a single institution experience
F42The link between obesity and advanced breast cancer is a matter of much interest
F43Neoadjuvant Chemotherapy among Breast Cancer subtypes
F44Subcutaneous Trastuzumab (scT) and metronomic oral Vinorelbine (mVRL) combination in HER2 + ve advanced breast cancer (ABC) patients (pts)
F45The power of traditional prognostic factor and immunohistochemical (IHC) surrogate molecular subtypes of breast cancer (BC) in predicting neoadjuvant chemotherapy response
F46Nab-paclitaxel in clinical practice
F47A single centre pilot study aiming to determine the recommended dose (RD) of metronomic oral vinorelbine in combination with oral cyclophosphamide and bevacizumab in advanced breast cancer (ABC) patients
F48Pre and post anti Her-2 therapy era
F49Pertuzumab, Trastuzumab, Docetaxel
F50Eribulin vs. Eribulin + Bevacizumab in advanced-line treatment of Her-2 negative metastatic breast cancer
F51Adjuvant endocrine therapy in elderly patient in early Breast Cancer, a less toxic therapy, is it really true? A single institution, “real life” experience
F52Evaluation of quality of life in early breast cancer disease free survivors. a cross sectional survey
F53No significant association between four chromosome 18 gene variants and breast cancer in an Italian cohort of patients
F54Neoadjuvant TAC-chemotherapy (taxotere adriblastina cyclophosphamide) in locally advanced breast cancer patients
F55Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients
F56Concomitantly epirubicin and trastuzumab (the Buzdar Regimen) as neo-adjuvant chemotherapy in HER2-overexpressed early breast cancer
F57(R)-a-Lipoic acid for the treatment of peripheral neuropathy in breast cancer patients (BCP) receiving adjuvant (A) or neoadjuvant (N) paclitaxel (P)
F58Effectiveness and safety of Everolimus-Exemestane (EVE-EXE) in unselected patients (pts) with HR + /HER2- Metastatic Breast Cancer (MBC)
F59Docetaxel and stealth liposomal doxorubicin in relapsed breast cancer as salvage treatment
G01*Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer patients
G02Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrence ovarian cancer ( ROC) patients with BRCA 1/2 mutation. A monoistitutional experience
G03Cervical cancer prevention in Uganda
G04Quality of life (QOL) analysis of the MITO8 phase 3 trial, a collaboration of MITO, Mango, AGO Study Group, BGOG, ENGOT, and GCIG
G05Post-menopausal ovary cancer is enriched of Ddx4+ primordial oogones as putative cancer stem cells
G06Trabectedin in combination with pegylated liposomal doxorubicin for patients with ovarian cancer
G07The complex management and treatment of hydatidiform mole
G08Feasibility and Tolerability of Intraperitoneal Chemotherapy in Ovarian Cancer
G09Multidisciplinary management in ovarian cancer
H01*Cross-validation of the care dependency scale in patients with cancer
H02*Efficacy of cryotherapy in paclitaxel-induced nail toxicity
H03*The red thread between Piacenza and the Michigan Appropriateness guide for intravenous catheters guidelines
H04*Chemotherapy extravasation
H05*Peripherally Inserted Central Catheter
H06The role of psychosocial status in the change of lifestyles in patients with colorectal cancer in follow up
H07From scientific evidence to clinical practice in cancer patients
H08Safeguard the patient's life by working in security
H09The home self-monitoring of symptoms after chemotherapy in cancer patients with the use of ESAS scale
H10The role of the study nurse in clinical research
H11Nursing experience and practice on Peripherally Inserted Central Catheters in adult cancer and not-cancer patients
H12A phenomenological study exploring the experiences of protective isolation in patients undergoing allogeneic Haematopoietic Stem Cell Transplantation
H13Midline for home palliative care
H14Sleep disorder in cancer patients undergoing chemotherapy
H15Central venous catheters in oncology. comparison of materials for prevention of complications
H16Head and Neck cancer
H17Qualitative analysis about adherence to oral hormonal therapy in patients with prostate cancer
H18Anxiety and depression in oncology patients with chronic pain
L01Individual patient data meta-analysis of the impact of treatment expertise on the outcome of head and neck cancer patients treated within 6 randomized trials
L02Individual ADCC capability predict treatment outcome under cetuximab-based therapy in head and neck cancer?
L03Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer
L04RANK expression in EBV associated nasopharyngeal cancer metastasis in non-endemic setting
L05Prognostic value of hpv infection by e1 detection and p16 expression in 78 oropharyngeal squamous cell carcinomas
L06Analysis of patients' preferences for post-treatment clinical follow-up in head and neck cancers
L07A randomized phase II study for tertiary prevention of squamocellular cancer of head and neck (SCCHN) with a dietary intervention
L08Pre-operative chemotherapy in locally advanced but technically resectable oral cavity squamous cell carcinoma
L09Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients
L10An added value to Multidisciplinary Team
L11Prognostic impact of weight loss variation and nutritional parameters in patients affected by locally advanced or metastatic Head Neck Cancer (HNC)
L12Radiotherapy and cetuximab for elderly patients affected by loco-regionally advanced head and neck cancer
L13Methotrexate chemotherapy in elderly patients with locally advanced head and neck cancer
L14Complete remission of bone metastases in androgen receptor - positive (ar+) salivary duct carcinoma (sdc) of the parotid treated with radium 223
L15The lived experience of nutritional impact symptoms during treatment for head and neck cancer patients
M01The incidence and relative risk of pulmonary toxicity (PT) in patients treated with anti-PD-1/PD-L1 targeted therapies for solid tumors
M02CARAMEL study
M03Phosphoinositide-3-kinase single-nucleotide polymorphisms frequencies between malignant melanoma patients and healthy volunteers shared by sex
M04Follow-up schedule based on evidence of melanoma recurrences in 200 patients, a monoinstitutional experience
M05Retreatment with Vismodegib is active in progressive advanced Basal Cell Carcinoma
M06Screening of malignant melanoma (MM) by miRNA
M07BRAF, NRAS and C-KIT mutations segregate distinct clinical and histopathological profiles in patients with melanoma
M08Monoinstitutional experience of vemurafenib and cobimetinib for BRAF mutated metastatic melanoma
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer
N01The psychological consequences after adjuvant aromatase inhibitor therapy in breast cancer women
N02Mindfulness-based Stress Reduction (MBSR) in cancer patients
N03The impact of Aggressiveness and Depression in Burn-out among operators in Oncology
N04The effects of Emotional Disclosure interventions through Writing in Cancer Patients
N05Distress assessment in cancer patients in DH setting
N06The role of factors affecting worry and risk perception of breast cancer in a chemoprevention trial of tamoxifen
N07The family, essential resource in the care process
N08Mood and distress in cancer patients after Autogenic Training (AT)
N09Empathic communication for reduction of pain perception and anxiety in patients implanted central venous accesses for cancer therapy
N10What type of psychological aspects impact on dietary habits and weight gain, in breast cancer adjuvant therapy?
N11Evaluation of burnout syndrome and personalized intervention in the medical oncology unit of second university of naples (sun)
N12Interactive waiting room project
N13Body image and sexuality in women with breast and gynaecological cancer
N14Screening for distress in everyday oncology practice
N15Screening of Psychological Distress in cancer patients at Oncological Reception Centre. Preliminary results
N16The role of psychological flexibility in cancer patient with pain
N17Customer Satisfaction of CAS (Centro Accoglienza e Servizi) Dr. ssa Roberta Fornara2, Dr. Elena Castiglioni1, Dr. Alice Gatti1, CPSI Monica Bacchetta1, Dr. Incoronata Romaniello1 1 SSVD di Oncologia -Ospedale SS Trinità di Borgomanero- ASL NO 2 Servizio di Psicologia ASL NO
N18An Etiquette-Based Medicine Decalogue on the Professional style in the Multidisciplinary Unit (UVM) of Cosenza Hospital Oncology Department
N19Psychological Rehabilitation in Oncology
N20Psychological assistance and monitoring of oncological patients' quality of life
P01A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor α (pdgfrα) monoclonal antibody, in advanced soft tissue sarcoma (sts)
P02Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in advanced leiomyosarcoma and angiosarcoma
P03Biological effects of cabozantinib on osteosarcoma-bone microenvironment model
P04Systemic therapy in clear cell sarcoma (CCS)
P05Local treatment with electrochemotherapy of superficial angiosarcomas
P06Multimodal approach of pulmonary artery sarcoma
P07Recombinant granulocyte colony-stimulating factors (rG-CSFs) in the management of NEUtropenia induced by anthracyclines and ifosfamide in patients with soft tissue SARcomas (NEUSAR)
P08Neoadjuvant treatment of a duodenal GIST revealed a new imatinib-sensitive exon 11 c-KIT-mutation
P09ReCaTuR -Rare Cancer Network Calabria -“Implementing a software system based on showing of 3D stereoscopic imaging data”
R01Efficacy and safety of oral Morphine versus oral Prolonged-Release Oxycodone/Naloxone in opioid-naïve cancer patients
R02Efficacy and safety of oral Prolonged-Release Oxycodone/Naloxone in opioid-naïve cancer patients
R03Knowledge, attitudes and associated behaviors of young Italian medical oncologists in management of cancer pain
R04High dosages of the fixed combination OXYCODONE/NALOXONE in cancer pain
R05Off-label drugs use in home care
R06Depressive symptom and oncological uncontrolled pain
R07Clinical governance and appropriateness of opioid-prescribing practices in cancer pain
R08Occasional sedation in the management of cancer pain
R09Systematic pain evaluation in hospitalized cancer patients in a Medical Oncology Unit
R10Painting the pain
R11Mucositis pain
R12Survey on prevalence and management of breakthrough cancer pain
R13Tapentadol PR for patients with advanced cancer pain
R14Tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain
R15Managing cancer pain with tapentadol PR
R16Potentiation and tolerance preservation of morphine induced analgesia in rodents and healthy volunteers
R17Adherence to opioid treatment in patients with chronic cancer pain
R18Osteopathy for Post-Mastectomy Pain Syndrome (PMPS) in early breast cancer (EBC) patients
R19Clinical management of breakthrough cancer pain in patients with malignancies of the District Head - Neck
R20Management of breakthrough cancer pain (BTcP) in patients with bone metastases of solid tumors
S01Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS)
S02Oral Anticancer Therapy Project
S03The role of clinical risk in Low Grade Glioma patients in the era of genomic medicine
S04External Quality Assessment Schemes in the management of solid tumors
S05Management of hepatitis C positive patients undergoing active treatment for malignancies
S06Efficacy of antibiotic prophylaxis with tetracyclines for EGFR induced skin rash
S07Epidemiology and Prognostic factors for NETs in Italy
S08Cross-cultural adaptation of the US National Cancer Institute's PRO-CTCAE instrument into Italian for adult cancer patients
S09Patient-caregiver relationship in cancer movies of the last ten years
S10Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in italy
S11Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy
S12Narrative Medicine
S13The effect of financial difficulties on clinical outcomes in Italian cancer patients
S14The drug day an effective strategy for the containment of pharmaceutical costs
S15Towards the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma
S16Clinical Trial Units in Italy
S17Antiemetic prophylaxis (AP) in our clinical practice
S18AIFA Determination 809/2015 on Phase I Clinical Trials
S19Impact of Hyponatremia in a Tertiary Cancer Center
S20Symptoms leading advanced cancer patients to ask the emergency department for assistance
S21Use of Complementary and Alternative Medicine (CAM) in cancer patients
S22ERA-Net TRANSCAN JTC 2011
S23Anaplastic Astrocytoma (AA) and Glioblastoma (GBM)
S24The follow-up and lifestyle (FUCSAM project). Oncology Network of Piemonte and Valle d'Aosta (ROPVdA)
S25Real-word analysis on the use of somatostatin analogs (SSAs) in patients with neuroendocrine neoplasms (NENs)
S26MGMT promoter methylation status in glioblastoma (GBM) patients
S27The patients' understanding of clinical research
S28The impact of the clinical pharmacist (CP) in reporting suspected adverse drug reactions (ADRs)
S29Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies - THE CORNUCOPIA STUDY
S30Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?
S31A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and Temozolomide (TMZ)
S32English Language in Oncology
S33Biological effects of Cabozantinib on bone microenvironment
S34Phase I cancer clinical trials in Italy
S35Innovative approaches to establish and characterize primary cultures
S36Exosomes derived by melanoma cells promote the tumor osteotropism
S37Saving in clinical trial
S38Feasibility and outcomes of a nordic walking program for women following breast or ovarian cancer treatments
S39IL-17A drives the OC-like transdifferentiation of malignant plasma cells in multiple myeloma
S40How to enhance nonprofit clinical research in a General Hospital
S41G1-G2 Neuroendocrine Tumors (WD NET) in treatment with Capecitabine (Cp) plus somatostatin analog (SSA)
S42Complete response to avelumab in Merkel Cell Carcinoma, and potential correlation with toxicity
S43ZeOxaNMulti trial
S44Transdermal granisetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (cinv) in patients with locally advanced head-neck squamous cell cancer (hnscc) treated with radiotherapy plus concomitant administration of cisplatin
S45Retrospective analysis of patients affected by diffuse large B cell lymphomas AIDS-related
S46Toxicity of targeted therapy in elderly patients
S47A retrospective analysis to evaluted the off-label use Bevacizumab in recurrent malignant gliomas
S48The value of a tailored evaluation before cancer therapy
S49Primary hepatic lymphoma
S50Observational study about the adherence to the Mediterranean diet and lifestyle analysis in geriatric cancer patients in Salento
S51Oncogeriatric Unit
S52FUCSAM
S53Osteotropism of NETs
S54Transdermal granisetron is effective in prevention of acute-delayed emesis in patients with glioblastoma multiforme (gbm) treated with temozolomide (tmz)
S55Onset of fatigue in breast cancer patients
S56Eltrombopag low doses as prophilaxisof Chemotherapy-induced thrombocytopenia (CIT) in cancer patients treated with platinum based chemotherapy
S57Agnostos precision medicine project
S58State of the art of the Veneto Oncology Network (ROV) A two-year experience
S59Prospective observational pilot study on the BTcP evaluation in cancer patients.
S60Libro Blu
S61NAB-PACLITAXEL (NAB-P)
S62The role of second and further therapy lines in clinical practice. A monoinstitutional survey
S63Treatment of Kaposi's Sarcoma (KS) with nab-paclitaxel
S64Complementary therapies in cancer care an overview of the early italian experiences
S65Hospice palliative sedation in non-cancer patient
Author Index